Paediatric non-progression following grandmother-to-child HIV transmission by Tsai, M.-H. et al.
Tsai et al. Retrovirology  (2016) 13:65 
DOI 10.1186/s12977-016-0300-y
RESEARCH
Paediatric non-progression 
following grandmother-to-child HIV 
transmission
M.‑H. Tsai1†, M. Muenchhoff1†, E. Adland1, A. Carlqvist1, J. Roider1, D. K. Cole2, A. K. Sewell2, J. Carlson3, 
T. Ndung’u4,5,6 and P. J. R. Goulder1,4*
Abstract 
Background: In contrast to adult HIV infection, where slow disease progression is strongly linked to immune control 
of HIV mediated by protective HLA class I molecules such as HLA‑B*81:01, the mechanisms by which a minority 
of HIV‑infected children maintain normal‑for‑age CD4 counts and remain clinically healthy appear to be HLA class 
I‑independent and are largely unknown. To better understand these mechanisms, we here studied a HIV‑infected 
South African female, who remained a non‑progressor throughout childhood.
Results: Phylogenetic analysis of viral sequences in the HIV‑infected family members, together with the history of 
grand‑maternal breast‑feeding, indicated that, unusually, the non‑progressor child had been infected via grand‑
mother‑to‑child transmission. Although HLA‑B*81:01 was expressed by both grandmother and grand‑daughter, 
autologous virus in each subject encoded an escape mutation L188F within the immunodominant HLA‑B*81:01‑
restricted Gag‑specific epitope TL9 (TPQDLNTML, Gag 180–188). Since the transmitted virus can influence paediatric 
and adult HIV disease progression, we investigated the impact of the L188F mutant on replicative capacity. When this 
variant was introduced into three distinct HIV clones in vitro, viral replicative capacity was abrogated altogether. How‑
ever, a virus constructed using the gag sequence of the non‑progressor child replicated as efficiently as wildtype virus.
Conclusion: These findings suggest alternative sequences of events: the transmission of the uncompensated low 
fitness L188F to both children, potentially contributing to slow progression in both, consistent with previous studies 
indicating that disease progression in children can be influenced by the replicative capacity of the transmitted virus; 
or the transmission of fully compensated virus, and slow progression here principally the result of HLA‑independent 
host‑specific factors, yet to be defined.
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Background
In the absence of antiretroviral therapy (ART), HIV 
infected children normally progress to disease rapidly, 
approximately 50  % developing AIDS by 1  year of life, 
and by 2 years of life 50 % have died. In adult infection 
these times are 10 and 11  years, respectively [1]. For 
these reasons, in 2013 the WHO have recommended 
that ART should be initiated in all HIV-infected chil-
dren aged <5  years, and also in HIV-infected children 
whose absolute CD4 counts are <500 cells/mm3 (http://
www.who.int/hiv/pub/guidelines/arv2013/intro/execu-
tivesummary/en). There remain, however, a number of 
ART-naïve, HIV-infected children, aged <5  years whose 
absolute CD4 counts are >500  cells/mm3 and who rep-
resent approximately 10–15 % of infected children, who 
are relative slow progressors [2–4]. Approximately one-
third of the children within this group, therefore ~5 % of 
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all infected children, have absolute CD4 counts of >750 
cells/mm3,  that are therefore indistinguishable from 
those of age-matched HIV-uninfected children (10th–
90th  centiles; [5, 6]). Study of these slow-progressor 
children provides the opportunity to gain insights into 
mechanisms of non-pathogenicity in HIV infection that 
appear to differ substantially from those operating in 
adult infection [7, 8].
Long-term non-progressing HIV-infected adults tend 
to maintain high CD4 counts in the setting of low viral 
loads, so-called ‘elite’ controllers having undetectable 
viraemia [9]. Protective HLA class I molecules such as 
HLA-B*27, HLA-B*57, HLA-B*58:01 and HLA-B*81:01 
are highly enriched amongst adult elite controllers [9–
11]. The mechanisms proposed for HLA-associated con-
trol of HIV include the ability of these ‘protective’ HLA 
molecules to present Gag-specific epitopes for recogni-
tion by CD8+ T-cells to facilitate rapid killing of virus-
infected target cells [12, 13]. In these cases, the location 
of the epitopes, often in highly conserved regions of the 
capsid protein, may compromise the ability of the virus 
to select escape mutants that do not incur substantial 
costs to viral replicative capacity as a consequence [14]. 
In contrast, ‘protective’ HLA molecules are not expressed 
at high frequency in long-term non-progressing children 
[15]. The reasons for the lack of impact of ‘protective’ 
HLA in children may relate to immune ontogeny [1, 7] 
and the inability of young children to generate especially 
strong Th1 type CD4 T-cell responses. Although HIV-
specific CD8+ T-cell responses are detectable from birth 
in utero infected children [16, 17], these responses usu-
ally do not have a significant impact on viral replication, 
at least for the first years of life [15].
In contrast to HLA type, the viral replicative capacity 
of transmitted virus has a significant impact on disease 
progression in both paediatric and adult infection [15, 
18, 19]. We here studied the role of HLA and viral rep-
licative capacity in a family including three HIV-infected 
individuals, all expressing HLA-B*81:01, an HLA allele 
that is highly protective in adult infection [9–11]. Two 
of these family members were slow progressor chil-
dren, the third was the mother of one child and grand-
mother of the other. In this case, it appears that the latter 
child was infected by breast milk transmission from the 
grandmother.
Methods
Study subjects
The slow progressor cohort of HIV-infected children has 
been previously described [15]. Informed consent was 
provided for participation of the subjects in the study. 
Ethics approval was given by the University of the Free 
State Ethics Committee, Bloemfontein, the Biomedical 
research Ethics Committee, University of KwaZulu-
Natal, Durban, and the Oxford Research Ethics Com-
mittee. Viral load in chronic infection was measured 
using the Roche Amplicor version 1.5 assay; CD4+ T cell 
counts were measured by flow cytometry.
Four-digit HLA typing of the Class I locus was per-
formed from genomic DNA as previously described [20] 
by sequence-based typing at the ASHI* accredited HLA 
typing laboratory, University of Oklahoma Health Sci-
ences Centre, USA. Exons 2 and 3 of HLA Class I were 
amplified by locus-specific PCR and then sequenced. 
Resolution of ambiguities was undertaken according to 
the ASHI committee recommendations.
Additional viral sequence analyses were performed on 
a previously described, multi-center cohorts: 1470 Afri-
can clade C Gag sequences from cohorts based in Dur-
ban [21], Bloemfontein [22] and Kimberley [23] South 
Africa, Zambia and the Thames Valley area of the United 
Kingdom [23].
IFN‑γ ELISPOT assays
IFN-γ enzyme-linked immunospot (Elispot) assays were 
performed as previously described [24, 25], using opti-
mally defined epitopes and 18mer overlapping pep-
tides (OLP) with input cells/well ranging from 30,000 to 
100,000. The number of specific spot-forming cells (SFC) 
was calculated by subtracting the mean number of spots 
in the negative control wells from the number of spots 
counted in each well. The magnitude of epitope-specific 
responses was calculated as SFC per million cells.
Site‑directed mutagenesis of NL4‑3, SK‑254, and SK‑254(M)
T186S, L188F, L188F/T190I mutations of HIV-1 Gag 
sequence were introduced into the HIV-1 subtype B 
NL4-3 plasmid (pNL4-3) and a patient-derived sub-
type C HIV-1 Gag-protease sequence (SK-254, Gen-
Bank accession number HM593258) respectively by 
using QuikChange Lightning site-directed mutagenesis 
kit (Agilent technologies) along with custom-designed 
mutagenesis forward and reversed primers. The forward 
primers are shown as follows (mutated codons shown in 
bold): 5′-CC CCA CAA GAT TTA AAT AGC ATG CTA 
AAC ACA GTG GG-3′ (NL4-3 Gag T186S); 5′-CA CAA 
GAT TTA AAT ACC ATG TTC AAC ACA GTG GGG 
GGA CAT CA-3′ (NL4-3 Gag L188F); 5′-CCA CAA 
GAT TTA AAT ACC ATG TTC AAC ATA GTG GGG 
GGA CAT CAA GCA G-3′ (NL4-3 Gag L188F/T190I); 
5′-CC CCA CAA GAT TTA AAC AGC ATG CTA AAT 
ACA GTG GG-3′ (SK-254 Gag T186S); 5′-CA CAA GAT 
TTA AAC ACC ATG TTC AAT ACA GTG GGG GGA 
CAT CA-3′ (SK-254 Gag L188F); 5′-CCA CAA GAT 
TTA AAC ACC ATG TTC AAT ATA GTG GGG GGA 
CAT CAA GCA G-3′ (SK-254 Gag L188F/T190I). In 
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addition, considering the six SK-254 variants in p24 Gag 
might affect viral fitness, we used QuikChange Light-
ning Multi site-directed mutagenesis kit (Agilent tech-
nologies) to retro-mutate these variants to Concensus 
C. The customised former primers are (mutated codons 
shown in bold): 5′-G CAA ATG GTA CAC CAA GCC 
ATA TCA CCT AGA ACT TTG AAT G-3′ (SK-254 
Gag T147I); 5′-AA ATA GCA TGG ATG ACT AGT A 
AC CCA CCT ATC CCA GTG GGA G-3′ (SK-254 Gag 
G252S/V256I); 5′-ACA CAA GAT GTA AAA AAT TGG 
ATG ACA GAT ACC TTG TTG GTC CAA-3′ (SK-254 
Gag E319D); 5′-C ATT TTA AGG GCA TTA GGA CCA 
GGA GCT ACG TTA GAA GAA ATG ATG ACA GCA 
TG-3′ (SK-254 Gag A340G/S342T) Hence, the p24 Gag 
in this modified SK-254 sequence (SK-254(M)) is the 
same as Consensus C. The reverse mutagenesis primers 
comprised the reverse complement of the forward prim-
ers shown. The other mutations Q182S, T190A, T190I, 
T186S/Q182S, T186S/T190A, and T186S/T190I were 
kindly engineered and provided by Dr. Jaclyn K. Wright 
(University of KwaZulu-Natal, Durban, South Africa). All 
the mutations were confirmed by sequencing.
Virus production and replication kinetics
All the plasmids were maxipreped according to manufac-
turer’s instruction (HiSpeed® plasmid Maxi Kit, Qiagen, 
Hilden, Germany) beforehand. To generate the mutant 
viruses, the mutated NL4-3 and SK-254, SK-254(M) 
Gag-Pro amplified PCR cleaned up products along with 
the BstE II (New England Biolabs, Ipswich, MA) lin-
earized pNL4-3Δgag-protease were transfected into 
GFP reporter GXR cells via electroporation in a BioRad 
GenePulsar II using 0.4  cm cuvettes at 300  V, 500  µF, 
and infinite resistance as previously described [14]. 
Virus propagation was then monitored by flow cytom-
etry to detect GFP-expressing infected cells in approxi-
mately 2 weeks in culture with GXR cells. Virus cultures 
supernatants were harvested mostly when 30  % of cells 
were GFP-positive. Viruses were aliquoted and stored at 
−80 °C until use. All the mutations were confirmed again 
by extracting viral RNA from the harvest supernatant 
and sequencing. The nucleotide identity was 99.92 %.
Along with WT as positive controls and two nega-
tive controls without viruses, NL4-3 and SK-254 mutant 
viruses were incubated with GXR cells in a 24-well plate 
for determination of viral titres, as previously described 
[26, 27]. The percentages of GXR-positive cells were 
measured by flow cytometry after 48  h. A low MOI 
(0.03 %) was set as the lowest threshold for determining 
the amount of virus required for inoculation. The GFP+ 
expression was measured from day 2 to 7(or 8) before 
it reached the saturated 30–40  %. The viral replication 
capacity was defined by the natural log calculation of 
the mean slope of exponential growth in Excel. This was 
further calibrated to the normalized value relative to the 
WT NL4-3, SK-254, and SK-254(M) respectively. All the 
assays were done at least in triplicate.
Amplification and sequencing of proviral DNA
Genomic DNA was extracted during the separation of 
PBMCs and the Gag sequences were then amplified by 
nested PCR as previously described [28, 29]. The prim-
ers of PCR reactions are: 5′-CTCTAGCAGTGGC 
GCCCGAA-3′ and 5′-TCCTTTCCACATTTCCAACAG 
CC-3′ for the first round; 5′-CAATTTCTGGCTATGTG 
CCC-3′ and 5′-ACTCGGCTTGCTGAAGTGC-3′ for 
the second. After PCR products purification (QIAquick 
PCR Purification Kit, Qiagen), BigDye Terminator v3.0 
Ready Reaction mix (Applied Biosystems) was applied for 
all the sequencing, with three pairs of primers: 5′-TCT 
CTC GAC GCA GGA CTC-3′, 5′-TTT CCA CAT TTC 
CAA CAG CC-3′, 5′-CTG CAC TAT AGG ATA ATT 
TTG AC-3′, 5′-GAC ACC AAG GAA GCC TTA G-3′, 
5′-CTC CCA CTG GAA CAG GTG-3′ and 5′-GGA ACA 
AAT AGC ATG GAT GAC-3′). The obtained sequences 
were run on the ABI 3700 DNA analyzer. As previ-
ously described [23], Sequences were analyzed by using 
Sequencher v5.0.1 (Gene Codes Corporation). HXB 
sequence was used as a reference for all residue numbers.
Phylogenetic analysis
A maximum likelihood phylogenetic tree using the gen-
eral time reversible model of nucleotide substitution was 
constructed with 1000 bootstrap replicates using Mega 
7.0.14 software and viewed using FigTree v1.4.0 soft-
ware. Clade consensus sequence was generated using the 
Gag-Protease sequence and the Simple Consensus Maker 
tool available from the Los Alamos HIV database (http://
www.hiv.lanl.gov/). Forty-three Gag-Protease C clade ref-
erence sequences from Durban, South Africa, from the 
same locality as the study subjects GM, GD and D2, were 
included as reference sequences.
Structural modelling
The p24-Gag protein (from PDB: 1GWP) was used to 
model known mutations in the virus. Sequences were 
adjusted with COOT [30] and graphical representations 
were prepared with PYMOL (The PyMol Molecular 
Graphics System, Schrodinger, LLC).
Results
Identification of a pediatric slow progressor infected 
via grandmother‑to‑child transmission
We have previously defined ‘paediatric slow progres-
sors’ as ART-naïve, HIV-infected children who have 
not progressed to meet clinical or CD4 count criteria 
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for ART initiation [15]. The CD4 count criteria for ART 
initiation in children aged >5 years in South Africa until 
2013 was an absolute CD4 count of ≤350 cells/ul [15]. 
Within a study cohort of paediatric slow progressors in 
Durban, South Africa, a female (‘GD’) was enrolled at 
age 9.1 years, with an absolute CD4 count of 830 cells/
ul and viral load of 42,000 copies/ml (Fig.  1a). The 
mother (‘D1’) of GD, however, tested HIV-uninfected. 
It emerged that the HIV-infected grandmother (‘GM’) 
of GD had a second daughter (‘D2’) who was born 
5 weeks after GD (Fig. 1b), and that GM had breast-fed 
both her daughter (D2) and her grand-daughter (GD). 
Phylogenetic analysis (Fig.  1c) of HIV Gag sequences 
obtained from GM, D2 and GD were consistent with 
mother-to-child transmission of HIV from GM to D2, 
and with grandmother-to-child transmission of HIV 
from GM to GD.
Rare mutation Gag‑L188F within HLA‑B*81:01‑TL9 epitope 
shared by transmission trio
Both GD and D2 were pediatric slow progressors, as 
defined by the criteria of reaching 5  years of age, ART-
naive, with an absolute CD4 count of >350 ul (Additional 
file 1: Table S1). In case of D2, ART was initiated at age 
6.7 years despite a relatively high CD4 count of 625 cells/
mm3, but because of TB infection. Factors that might 
contribute to slow disease progression in related fam-
ily members would include viral factors and shared host 
genetic factors. We first sought to test the hypothesis 
that slow disease progression in GD and D2 might be 
related to common infection by transmission from GM 
of a virus with low replicative capacity, since viral replica-
tive capacity has been shown to play an important role 
in disease progression in both paediatric and adult HIV 
infection [15, 18], We focused on the Gag region, since 
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Fig. 1 Grandmother‑to‑child transmission in a non‑progressing child. a Viral load and absolute CD4 count in non‑progressing, ART‑naive child 
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previous studies have demonstrated a strong correlation 
between Gag mutants, viral replicative capacity and dis-
ease outcome in both adults and pediatric infection [15, 
18, 31]. The virus in all family members GM, D2 and 
GD expressed the mutation Gag-L188F (Table  1). This 
mutant arises at the carboxy-terminal anchor residue 
of the HLA-B*81:01-TL9 epitope (TPQDLNTML, Gag 
180–188). This variant is rare, being observed in <0.2 % 
of published sequences (http://www.hiv.lanl.gov/) but is 
strongly associated with expression of HLA-B*81:01 from 
previous large cohort studies of C clade infection [32] 
(Fig. 1d, p = 6.3 × 10−7, q = 0.0008). These data are con-
sistent either with L188F being an escape mutant driven 
by the HLA-B*81:01-TL9 response in GM and transmit-
ted to both GD and D2; or being selected independently 
in each of the three family members, all of whom express 
HLA-B*81:01 (Additional file 1: Table S1).
Impact of L188F on viral replicative capacity
Previous studies [27, 33] have demonstrated that the most 
common escape variants within the HLA-B*81:01-TL9 
epitope, T186S and Q182S/T186S (Table  1), can have a 
substantial impact on viral replicative capacity (VRC). 
To investigate the possibility that this rare L188F mutant 
might similarly affect VRC, thereby contributing to slow 
progression observed in subjects GD and D2, this vari-
ant was generated by site-directed mutagenesis and the 
replicative capacity compared with the more common 
and well-described HLA-B*81:01-associated TL9 escape 
mutants, T186S, the combination of T186S/Q182S, and 
the putative compensatory mutants T190A and T190I 
(33; Table 1). These comparisons were undertaken using 
3 different viral backbones: the laboratory-adapted B 
clade virus NL4-3; a chimeric virus comprising NL4-3 
with Gag-Pro inserted from a C clade infected South 
African subject SK-254, whose viral sequence is similar to 
the C clade consensus [33]; and a chimeric virus, referred 
to here as SK-254(M), comprising NL4-3 with the same 
Gag-Pro inserted from the C clade infected South Afri-
can subject SK-254, but with the necessary retro-muta-
tions made to enable the viral amino acid sequence to be 
identical with the C clade consensus (Additional file  2: 
Table S2).
The VRC determined for each mutant virus is shown 
relative to NL4-3, SK-254, and SK-254(M) respectively 
(Fig. 2). Irrespective of the backbone, any viruses encod-
ing L188F or T186S were incapable of replicating at 
a sufficient level in  vitro to measure VRC. Although 
Table 1 Differences in autologous Gag sequences between grandmother, grand-daughter and daughter-2, TL9 variants 
tested and their frequency in HIV-infected adults
Subject Gag sequence
Consensus
(Gag residue) 
 I…VHQAISPRTL…KAFSPEVIPMF…TPQDLNTMLNT…HPVHAGPIAPGQMR……A……T……T……
 134   146-7                167           188           218-9         228   248  332 347
Grand-mother V…---PL-----…------I----…--------F--…--AQ--------I-……T……-……I……
Daughter-1 N/A 
Daughter-2 V…---PL-----…------I----…--------F--…--VQ--------I-……T……-……I……
Grand-daughter V…---PL-----…------I----…--------F--…--AQ--------I-……A……-……I……
B*81:01-TL9 Frequency in 
B*81+ves† 
Frequency in
B*81-vesTPQDLNTMLNT
Variants tested WT ----------- 34.2% 85.6%
T186S ------S----    17.1%    0.6%
Q182S --S--------      0.0%    1.9%
T190A ----------A      0.0%    0.3%
T186S/Q182S --S---S----    12.8%    0.6%
T186S/T190A ------S---A      0.9%    0.5%
T186S/T190I ------S---I      1.8%    0.8%
L188F --------F--      1.8% †    0.1%
L188F/T190I --------F-I      0.0%    0.0%
Variants not tested    31.4%   10.6%
† The frequency is of the variant shown only; for example other variants in combination with L188F such as Q182S/L188F are found in the study cohort but these 
variants were not tested
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GFP+ expression in target cells remained negative up 
to >100  days in culture, viral RNA was successfully 
extracted from the supernatant and the respective L188F 
and T186S mutations, confirmed by sequencing. This 
would indicate that the viruses were generated and rep-
licating, although insufficiently to assay VRC. The second 
observation here is that the viral backbone has a consid-
erable influence on the impact that individual variants 
may make on VRC. For example, T190I shows a modest 
compensatory effect in combination with L188F in NL4-
3, but not in SK-254 or SK-254(M). In relation to T186S, 
T190A and T190I are compensatory in the setting of 
NL4-3, but only T190I in the context of SK254 and only 
T190A in the context of SK254(M). Of note, however, the 
entire Gag-Pro sequence taken from GD to form a chi-
meric virus with NL4-3 replicated as well as SK-254(M) 
WT, despite containing the L188F variant. This indicates 
that one or more of the additional variants within the 
Gag-Pro sequence of the GD were capable of compen-
sating for L188F. We were not able to generate chimeric 
viruses from the GM or D2 samples available but these 
differed in sequence by only two and one residue from 
that of GD, respectively (Table 1).
Structural analysis indicates likely mechanism of L188F 
and T186S impact on VRC
In order to better understand why the HLA-B*81:01-
driven escape mutants L188F and T186S have such a 
marked impact on VRC, we analyzed these mutants 
using previously solved crystal structures of the cap-
sid protein [34–37]. The capsid protein comprises an 
amino-terminal domain (NTD: Gag 133–283) linked to 
a carboxy-terminal domain (CTD: Gag 284–363); the 
main features of the NTD are an N-terminal beta-hair-
pin loop, 7 α-helices, and the cyclophilin binding loop 
linking helices-4 and-5 (Fig.  3a). The TL9 epitope (Gag 
180–188) is located almost exactly within helix-3 (Gag 
residues 181–189).
To consider the impact of the L188F escape mutant, 
the contacts between 188-Leu and neighboring resi-
dues 184L, 198M, 201L and 266I were identified, these 
forming 7 van der Waals interactions, in addition to the 
hydrogen bond between the backbone amine group at 
residue 188 and the backbone carbonyl group at residue 
184 (Fig. 3b). Modeling of the L188F substitution would 
indicate that all but one of these 7 van der Waals interac-
tions are disrupted (Fig.  3c), thereby likely substantially 
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destabilizing the interface between helices-3 and -4. Sim-
ilarly, modeling would suggest that the consequence of 
the T186S escape mutant would be to abrogate 3 of 4 van 
der Waals interactions between 186-Thr on helix-3 and 
152-Leu and 147-Ile on helix-1 (Fig. 3d). The destabiliz-
ing impact of this would, however, be largely mitigated 
by the compensatory T190I mutation, in providing 3 new 
van der Waals interactions between 190-Ile and 152-Leu 
(Fig. 3e). However, the variable ability of variants at 190-
Thr to compensate successfully for the fitness cost of the 
T186S escape mutant according to viral backbone (NL4-
3, SK-254 or SK-254(M)) is not explained by these mod-
els, with the majority of the differences between these 
viruses located within the carboxy-terminal domain 
(Additional file 2: Table S2).
Discussion
These studies describe two HIV-infected, genetically 
related children, born within 5  weeks of one another, 
both of whom progressed slowly to disease. One child 
was infected via mother-to-child transmission and the 
other, more unusually, was infected by the same donor, 
but via grandmother-to-child transmission. This scenario 
raised the question of whether slow progression in the 
two genetically related children could be related to the 
virus transmitted, or to shared host factors. The donor, 
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‘GM’, the grand-daughter, ‘GD’, and the HIV-infected 
daughter, ‘D2’, all expressed HLA-B*81:01, which is nor-
mally associated with protection against disease pro-
gression in adult infection [10, 11]. Autologous virus in 
each of the three family members also shared the same, 
rare, L188F mutation, which is strongly associated with 
HLA-B*81:01, and lies at the carboxy-terminus of the 
immunodominant HLA-B*81:01-restricted Gag epitope 
TL9 (TPQDLNTML, Gag 180–188). In common with 
the more frequent HLA-B*81:01-TL9 escape mutation 
T186S, the L188F variant almost completely prevented 
viral replication when introduced into heterologous HIV 
strains. However, the replicative capacity of virus encod-
ing the entire grand-daughter (GD) Gag sequence did no 
differ from wildtype virus. It remains entirely possible (as 
discussed further below) that either the uncompensated 
L188F variant was transmitted to both daughters, or that 
wildtype virus was transmitted and L188F plus the near-
identical compensatory mutants were selected indepen-
dently post-transmission in GM, GD and D2. However, 
on the basis that low fitness viruses are less likely to be 
transmitted [32], the most parsimonious interpretation of 
these data may be that the fully compensated L188F virus 
was transmitted in both cases and that slow progression 
in the two children was not related to viral factors but to 
undefined host-specific factors.
Previous studies of the mutations selected within 
the HLA-B*81-TL9 epitope have similarly shown that 
the most frequent escape variant, T186S, can virtually 
abrogate viral replication [33]. Similar to the analyses 
reported here, the impact of T186S on viral replicative 
capacity varied considerably according to the nature of 
the viral backbone, as did the ability of variants such as 
T190I to rescue the virus from the fitness cost result-
ing from T186S [33]. The studies described here are 
highly consistent with these findings, in demonstrat-
ing, first, the dramatic negative impact of L188F, as well 
as T186S, on viral replicative capacity; and, second, the 
striking influence of viral sequence context. For example, 
T190I and not T190A was able to compensate for T186S 
in the SK-254 virus but the reverse was the case in the 
SK-254(M) virus. The p24 Gag residues that might con-
tribute to the substantial influence of sequence context 
on the impact of the TL9 escape mutants on viral repli-
cative capacity observed here include several that have 
been previously implicated as compensatory mutants [26, 
28, 38, 39], such those within the cyclophilin A binding 
loop (V218A, H219Q and M228T), and the Gag tropism-
determining loops (Gag residues 137–147; and Gag 248–
254) [40].
The lack of samples at the time of transmission 
means that the sequences of the viruses that were 
transmitted are unknown. It is possible therefore 
that the same L188F variant within the B*81:01-TL9 
epitope was selected independently from the wildtype 
TL9 sequence in all three family members subsequent 
to transmission, since all three individuals expressed 
HLA-B*81:01. If this were the case, it is likely that the 
virus transmitted by GD without L188F would have had 
normal viral replicative capacity, at least on the basis 
of the otherwise unremarkable gag sequence in these 
three family members. In the more likely scenario of 
the virus encoding L188F being transmitted both to 
GD and D2, the fact that this virus was fully compen-
sated in GD suggests that low viral replicative capacity 
is unlikely to have contributed to slow progression in 
the two children.
These observations would suggest therefore that unde-
fined host factors are more likely to have contributed to 
slow progression in the two genetically related children. 
Although in this case both children expressed HLA-
B*81:01 that is associated with slow progression in adult 
infection, large cohort studies indicate that ‘protective’ 
HLA alleles, such as HLA-B*57, HLA-B*58:01 and HLA-
B*81:01, do not significantly influence paediatric dis-
ease progression [15]. Furthermore, in a small series of 
HLA-B*27-positive HIV-infected children, any benefit to 
the child of expressing HLA-B*27 was negated in instances 
where the HLA-B*27-mother transmitted an escape 
mutant in the critical HLA-B*27 Gag epitope [41]. In the 
current study, no HLA-B*81:01-TL9 response was detect-
able in the child GD (Additional file 3: Figure S1), suggest-
ing that this response is not critical to non-progression. 
Furthermore, in keeping with other non-progressor chil-
dren [8, 42], normal-for-age CD4 counts were maintained 
in GD through childhood despite relatively high viral loads 
(between 38,000 and 140,000 between 9 and 12  years of 
age). HLA-mediated control of viremia that is characteris-
tic of adult non-progression [12] is not a typical feature of 
non-progressive paediatric infection. In common with the 
natural hosts of SIV in whom normal CD4 counts and low 
systemic immune activation are also maintained despite 
persistent high level viremia, the mechanisms underlying 
non-progression in paediatric infection differ very sub-
stantially from those operating among adult elite control-
lers [9] and remain incompletely defined.
One additional notable feature in this study is the 
occurrence of paediatric HIV infection in the absence 
of mother-to-child transmission. The particular scenario 
of grandmother-to-child transmission has not, to our 
knowledge, been described previously, but transmission 
via surrogate breast-feeding is a well-recognized cause 
of non-vertical, non-sexual HIV infection in children 
[43, 44]. The prevalence of paediatric transmission via 
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surrogate breast-feeding is unknown but, from data accu-
mulated within large studies of >250 infected children, 
this would likely represent approximately 1–2 % of pae-
diatric infections [45–47]. The relevance of grandmother-
to-child to non-progression is open to speculation, but 
certainly timing of transmission affects outcome in pae-
diatric infection, in utero infected children progressing 
faster than those infected intra-partum, and children 
infected post-partum via breast milk progressing the 
slowest [48].
Conclusion
These data are consistent with previous studies indicating 
that, compared to adult elite controllers, distinct mech-
anisms underlie slow HIV paediatric disease progres-
sion. The principal host factors responsible for disease 
non-progression in children appear not to include HLA 
class I and remain yet to be defined. Further evaluation 
of this group of paediatric slow progressors is therefore 
warranted.
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